Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Cassava Sciences Inc (FLNA) vs Mattel Inc (MAT) Price & Performance

Cassava Sciences IncTrade
Mattel IncTrade

Price performance (Past 24H)

Key statistics

Cassava Sciences Inc vs Mattel Inc — how do they compare? Cassava Sciences Inc trades at $0.97 (market cap $47.75M), while Mattel Inc trades at $15.05 (market cap $4.21B). The key difference: Mattel Inc is far larger — about 88.2× Cassava Sciences Inc's market cap, and Mattel Inc is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals.

FLNAMAT
Market Cap
$47.75M$4.21B
Sector
HealthConsumer Cyclical
52-Week High
$4.64$22.16
52-Week Low
$0.87$13.05
Enterprise Value
-$34.93M$6.44B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Cassava Sciences Inc

FLNA trades at $0.995, up 3.75% today, with a bearish technical signal from moving averages but neutral oscillators. The company reported three consecutive quarterly earnings beats, with Q2 2026 EPS of -$0.18 beating expectations of -$0.225. Financials show negative cash flows and profitability, with ROE at -55.79% and net income of -$90.97M in 2025. Analyst consensus is strongly positive with 8 buy ratings out of 12.

Despite operational losses, FLNA's consistent earnings beats and strong analyst support suggest potential upside if clinical developments progress. Key risks include sustained cash burn, lack of revenue, and dependence on successful drug trials for Tuberous Sclerosis Complex. The stock remains speculative with high volatility expected.

Mattel Inc

Mattel (MAT) trades at $14.79, up 2.07% with a bullish technical signal from moving averages. The company reported mixed Q2 2026 results with revenue growth of 10% but an earnings miss due to higher costs. Valuation appears reasonable with P/E of 11.03 and P/S of 0.82, while profitability metrics show strong ROE of 20.5% despite margin pressures from increased advertising expenses.

The stock presents a balanced opportunity with analyst consensus leaning bullish (53% buy ratings) but faces near-term headwinds from cost inflation and discretionary spending pressures. Long-term growth drivers include toy-based entertainment partnerships and digital gaming expansion, though execution risks and market volatility require careful monitoring.

Returns comparison

Trailing returns across standard periods

About Cassava Sciences Inc

Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease

Read more on FLNA

About Mattel Inc

Mattel markets toy products that are sold to its wholesale customers and direct to retail consumers. The company offers products for children and families, including toys for infants and preschoolers, girls and boys, youth electronics, handheld and other games, puzzles, educational toys, media-driven products, and plush and fashion-related toys. Mattel's owned portfolio includes Barbie, Hot Wheels, Fisher-Price, Thomas & Friends, and American Girl. In addition, it currently manufactures toy products for its segments both internally and externally (through manufacturing partners). Just over half of its net sales are in North America, while the remainder stem from international markets.

Read more on MAT